Ianalumab
( DrugBank: Ianalumab / KEGG DRUG: Ianalumab )
7 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 35 | Pemphigus | 1 |
| 46 | Malignant rheumatoid arthritis | 2 |
| 49 | Systemic lupus erythematosus | 21 |
| 53 | Sjogren syndrome | 31 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 61 | Autoimmune hemolytic anemia | 4 |
| 63 | Idiopathic thrombocytopenic purpura | 25 |
| 95 | Autoimmune hepatitis | 7 |
35. Pemphigus
Clinical trials : 120 / Drugs : 109 - (DrugBank : 40) / Drug target genes : 28 - Drug target pathways : 167
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
46. Malignant rheumatoid arthritis
Clinical trials : 4,543 / Drugs : 2,251 - (DrugBank : 390) / Drug target genes : 198 - Drug target pathways : 232
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
49. Systemic lupus erythematosus
Clinical trials : 1,227 / Drugs : 752 - (DrugBank : 175) / Drug target genes : 130 - Drug target pathways : 207
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
53. Sjogren syndrome
Clinical trials : 368 / Drugs : 277 - (DrugBank : 94) / Drug target genes : 62 - Drug target pathways : 186
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
61. Autoimmune hemolytic anemia
Clinical trials : 183 / Drugs : 119 - (DrugBank : 42) / Drug target genes : 31 - Drug target pathways : 156
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
63. Idiopathic thrombocytopenic purpura
Clinical trials : 575 / Drugs : 261 - (DrugBank : 64) / Drug target genes : 61 - Drug target pathways : 142
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
95. Autoimmune hepatitis
Clinical trials : 58 / Drugs : 56 - (DrugBank : 27) / Drug target genes : 23 - Drug target pathways : 114
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|